Moleculin Biotech is a pharmaceutical company focused on the treatment of resistant cancers. Co.'s technologies are based on discoveries made at MD Anderson Cancer Center (MD Anderson). Co.'s primary product candidates is Annamycin, for which Food and Drug Administration allowed an Investigational New Drug Application to go into effect for a Phase 1/2 trial for the treatment of relapsed or refractory acute myeloid leukemia. Co. also has a license agreement with MD Anderson pursuant to which Co. had been granted a license for the patent and technology rights related to its WP1066 Portfolio and its close analogs, molecules targeting the modulation of primary oncogenic transcription factors. The MBRX stock yearly return is shown above.
The yearly return on the MBRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MBRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|